Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tampere University Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07646223CT.gov Vancomycin Efficacy in Response to Dysbiosis in Atypical Colitis | — | Not Yet Recruiting | — | — | — |
NCT07477782CT.gov Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation | — | Not Yet Recruiting | — | — | — |
NCT05876182CT.gov Vancomycin in Primary Sclerosing Cholangitis in Italy | — | Recruiting | — | — | — |
NCT05376228CT.gov A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD | — | Unknown | — | — | — |
NCT02464020CT.gov A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inflammatory Bowel Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vancomycin (this asset) | Tampere University Hospital | P2 | B · 60 |
| Macrogols | Region Skane | P4 | A |
| Prucalopride | Region Skane | P4 | BBB |
| Marcaine | Cedars-Sinai Medical Center | P4 | BBB |
| Epinephrine | Cedars-Sinai Medical Center | P4 | BB |
| Dexasone | Cedars-Sinai Medical Center | P4 | BB |
| Sodium Phosphate | Region Skane | P3 | BB |
| Sodium Picosulfate | Region Skane | P3 | BB |
| Gastrografin | Region Skane | P3 | BB |
+23 more in the Inflammatory Bowel Disease cohort
Other indications for Vancomycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Sclerosing Cholangitis | — | P4 | BB · 71 |
| Methicillin-Resistant Staphylococcus Aureus Infectious Disease | — | P3 | BB · 68 |
| Childhood Neoplasm | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vancomycin in Inflammatory Bowel Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vancomycin-inflammatory-bowel-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →